AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15660234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic SCT nasal spray at a dose of 200 IU/day on alternating 15 days per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Number of subjects: 120
Study 15660234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic SCT nasal spray on 10 days consecutively per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Number of subjects: 120
Study 12814035 — intervention group
Group type: EXPERIMENTAL
Intervention: G115 100 mg bid for three months
Number of subjects: 92
Study 12814035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 10417580 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% glycolic acid
Number of subjects: 26
Study 10417580 — intervention group
Group type: COMPARATOR
Intervention: Jessner's solution
Number of subjects: 26
Study 8824658 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosage of 40 mg omeprazole
Number of subjects: 17
Study 8824658 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosage of 40 mg omeprazole
Number of subjects: 17
Study 2200557 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper midline incision
Number of subjects: 0
Study 2200557 — intervention group
Group type: COMPARATOR
Intervention: Transverse incision
Number of subjects: 0
Study 7012189 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 12
Study 7012189 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaopectate
Number of subjects: 12
Study 7012189 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 30853771 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CAMBRA treatment
Number of subjects: 460
Study 30853771 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 460
Study 27889837 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training intervention (12 weeks of supervised, progressive treadmill walking)
Number of subjects: 8
Study 26927479 — intervention group
Group type: EXPERIMENTAL
Intervention: APOLO-Bari program for one year in addition to treatment as usual
Number of subjects: 180
Study 26927479 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study 24433229 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media recruitment strategies (Facebook and Twitter)
Number of subjects: 751
Study 24433229 — intervention group
Group type: EXPERIMENTAL
Intervention: Online survey
Number of subjects: 751
Study 24433229 — intervention group
Group type: EXPERIMENTAL
Intervention: Email, phone, and text message contact
Number of subjects: 751
Study 24433229 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 751
Study 21921821 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-sprint training (SST)
Number of subjects: 30
Study 21921821 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-sprint training (LST)
Number of subjects: 30
Study 19324332 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult learners presented with scattered inconsistency in determiners.
Number of subjects: 0
Study 19324332 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult learners with low frequency determiners in consistent contexts.
Number of subjects: 0
Study 19324332 — intervention group
Group type: EXPERIMENTAL
Intervention: Child learners compared to adult learners.
Number of subjects: 0
Study 17300357 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Number of subjects: 10
Study 17300357 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 10
Study 17300357 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 10
Study 17300357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15080022 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 101
Study 12772414 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP combined with dexamethasone (DXM)
Number of subjects: 207
Study 12772414 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional methods including hyperbaric oxygen, vasodilator, energy preparation such as ATP, CoA, and dexamethasone)
Number of subjects: 207
Study 11377920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 16
Study 11377920 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study 9135404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled 100% oxygen
Number of subjects: 37
Study 9135404 — intervention group
Group type: COMPARATOR
Intervention: Inhaled air (control)
Number of subjects: 37
Study 8201695 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin chemotherapy (3 courses of 90 mg/m² given for 3 consecutive days at monthly intervals)
Number of subjects: 77
Study 8201695 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 77
Study 8201695 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin chemotherapy
Number of subjects: 77
Study 8201695 — intervention group
Group type: COMPARATOR
Intervention: Postoperative cisplatin chemotherapy and Observation
Number of subjects: 77
Study 3284752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (30-80 mg daily)
Number of subjects: 16
Study 3284752 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (150-400 mg daily)
Number of subjects: 16
Study 3284752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1297641 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen (750-mg tablet) after fasting
Number of subjects: 12
Study 1297641 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release naproxen (750-mg tablet) after a standard meal
Number of subjects: 12
Study 1297641 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen with food
Number of subjects: 12
Study 1297641 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release naproxen fasting vs postprandial
Number of subjects: 12
Study 593995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 8
Study 593995 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 8
Study 593995 — intervention group
Group type: COMPARATOR
Intervention: Control (normal smoking)
Number of subjects: 8
Study 31252661 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-s1 casein hydrolysate (ACH; Lactium®)
Number of subjects: 48
Study 31252661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29279300 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340
Study 29279300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study 26597952 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (30 mg twice per day for 14 days)
Number of subjects: 65
Study 26597952 — intervention group
Group type: COMPARATOR
Intervention: Control (100 ml saline twice per day for 14 days)
Number of subjects: 65
Study 25088832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound histogram features for acute toxicity assessment
Number of subjects: 34
Study 25088832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound histogram features for late toxicity assessment
Number of subjects: 34
Study 25088832 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 34
Study 23495538 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude condition
Number of subjects: 90
Study 23495538 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 90
Study 23495538 — intervention group
Group type: COMPARATOR
Intervention: Hassle condition
Number of subjects: 90
Study 18836845 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum procalcitonin (PCT) with a cut-off value of 0.85 ng/ml
Number of subjects: 57
Study 18836845 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte sedimentation rate (ESR)
Number of subjects: 57
Study 18836845 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 57
Study 18836845 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte count
Number of subjects: 57
Study 18836845 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PCT, ESR, and CRP
Number of subjects: 57
Study 17164307 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (10 g testosterone gel daily for 24 weeks)
Number of subjects: 88
Study 17164307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 24 weeks)
Number of subjects: 88
Study 15976211 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative field block plus rofecoxib, 50 mg preoperatively and for 5 days postoperatively (PLR)
Number of subjects: 75
Study 15976211 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bupivacaine field block and perioperative placebo (PL)
Number of subjects: 75
Study 15976211 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CONT)
Number of subjects: 75
Study 11999936 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush fitted with a modified orthodontic brush head (Braun Oral-B Plaque Remover 3D)
Number of subjects: 63
Study 11999936 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Reach Compact Medium)
Number of subjects: 63
Study 10210035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB, 2‐4 g daily)
Number of subjects: 215
Study 10210035 — intervention group
Group type: COMPARATOR
Intervention: Sodium Valproate (VPA, 1‐2 g daily)
Number of subjects: 215
Study 10210035 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 215
Study 10210035 — intervention group
Group type: COMPARATOR
Intervention: Sodium Valproate (VPA)
Number of subjects: 215
Study 7790126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported alcohol use
Number of subjects: 1387
Study 7790126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported tobacco use
Number of subjects: 1387
Study 7790126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported illicit drug use
Number of subjects: 1387
Study 7790126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk-taking
Number of subjects: 1387
Study 2219505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult‐II test (H‐II) positive
Number of subjects: 308
Study 2219505 — intervention group
Group type: COMPARATOR
Intervention: Hemoccult‐II test (H‐II) negative
Number of subjects: 308
Study 581782 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 16
Study 581782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 16
Study 581782 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 16
Study 581782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol
Number of subjects: 16
Study 581782 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 16
Study 581782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30765389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib with concomitant GAS therapy
Number of subjects: 333
Study 30765389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib without concomitant GAS therapy
Number of subjects: 333
Study 30765389 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 333
Study 28604926 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) 274 mg administered orally at bedtime for up to 25 weeks
Number of subjects: 126
Study 28604926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 28604926 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) 274 mg
Number of subjects: 126
Study 25353053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (TAD) 5mg coadministered with finasteride (FIN) 5mg once daily for 26 weeks
Number of subjects: 695
Study 25353053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) coadministered with finasteride (FIN) 5mg once daily for 26 weeks
Number of subjects: 695
Study 23339180 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS
Number of subjects: 14
Study 23339180 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS
Number of subjects: 14
Study 23339180 — intervention group
Group type: COMPARATOR
Intervention: 1 mA cathodal tDCS
Number of subjects: 14
Study 23339180 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 14
Study 20593411 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 785 (0.1, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously or 1 or 5 mg/kg intravenously)
Number of subjects: 72
Study 20593411 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 785
Number of subjects: 72
Study 20593411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19299508 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-press exercise only (LP group)
Number of subjects: 89
Study 19299508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip adduction combined with leg-press exercise (LPHA group)
Number of subjects: 89
Study 19299508 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 89
Study 17483532 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg subcutaneously daily
Number of subjects: 224
Study 17483532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 15470215 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg per day)
Number of subjects: 651
Study 15470215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study 12468786 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated wrist extension movements in patients with partial recovery
Number of subjects: 11
Study 12468786 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 11
Study 9583069 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic retroperitoneal uterine suspension (n = 32)
Number of subjects: 62
Study 9583069 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic laparoscopy (n = 30)
Number of subjects: 62
Study 7637176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg of droperidol added to buprenorphine
Number of subjects: 60
Study 7637176 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of droperidol added to buprenorphine
Number of subjects: 60
Study 7637176 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of droperidol added to buprenorphine
Number of subjects: 60
Study 7637176 — intervention group
Group type: COMPARATOR
Intervention: Only buprenorphine
Number of subjects: 60
Study 2759074 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic glucose-electrolyte solution
Number of subjects: 6
Study 2759074 — intervention group
Group type: COMPARATOR
Intervention: Control (no drink)
Number of subjects: 6
Study 1016774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic conditions (4% CO2)
Number of subjects: 14
Study 1016774 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 14
Study 31841542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification protocol (directing attention away from energy drink cues in Exp.1 and joystick push away in Exp.2)
Number of subjects: 226
Study 31841542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification protocol
Number of subjects: 226
Study 28959907 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + nDOX
Number of subjects: 45
Study 28959907 — intervention group
Group type: COMPARATOR
Intervention: SRP + DOX
Number of subjects: 45
Study 28959907 — intervention group
Group type: COMPARATOR
Intervention: SRP + placeboCH
Number of subjects: 45
Study 26897438 — intervention group
Group type: EXPERIMENTAL
Intervention: Body movement group (Group M) with 6% sevoflurane induction and initial maintenance concentration of 3%.
Number of subjects: 58
Study 26897438 — intervention group
Group type: COMPARATOR
Intervention: Central pupils group (Group C) with 6% sevoflurane induction and initial maintenance concentration of 3%.
Number of subjects: 58
Study 25012408 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care programme
Number of subjects: 338
Study 25012408 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 338
Study 22990343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Ulcer Prevention Program (PUPP)
Number of subjects: 133
Study 22990343 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice following AHRQ guidelines)
Number of subjects: 133
Study 22990343 — intervention group
Group type: EXPERIMENTAL
Intervention: PUPP
Number of subjects: 133
Study 20440479 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeball/estimated POP-Q examination
Number of subjects: 50
Study 20440479 — intervention group
Group type: COMPARATOR
Intervention: Measured POP-Q examination
Number of subjects: 50
Study 17375008 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm pulse dye laser therapy (PDL) with settings: spot diameter 5 mm, pulse duration 0.45 ms, fluence 9 J/cm2, 5 passes at 1 Hz, with cryogen spray cooling.
Number of subjects: 35
Study 17375008 — intervention group
Group type: EXPERIMENTAL
Intervention: 595 nm pulse dye laser therapy (PDL)
Number of subjects: 35
Study 17375008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cooling pulses only)
Number of subjects: 35
Study 15723981 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 6632
Study 15723981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6632
Study 12487007 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT 1 (10-20 Hz)
Number of subjects: 40
Study 12487007 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT 2 (80-100 Hz)
Number of subjects: 40
Study 12487007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical procedure without current)
Number of subjects: 40
Study 12487007 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study 9579389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascitic fluid from patients with cirrhosis
Number of subjects: 27
Study 9579389 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis effluent (PDE) from CAPD patients
Number of subjects: 27
Study 9579389 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal/plasma ratios of HA in cirrhotic patients
Number of subjects: 27
Study 9579389 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ascitic HA levels with interleukin‐1beta, interleukin‐6, and transforming growth factor‐beta
Number of subjects: 27
Study 7650078 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mgI/ml (100 ml, n = 17)
Number of subjects: 53
Study 7650078 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol 320 mgI/ml (100 ml, n = 13)
Number of subjects: 53
Study 7650078 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 300 mgI/ml (75 ml, n = 12)
Number of subjects: 53
Study 7650078 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol 300 mgI/ml (100 ml, n = 11)
Number of subjects: 53
Study 2711141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (673 men) received advice to reduce risk during two home visits and quarterly newsletters.
Number of subjects: 1373
Study 2711141 — intervention group
Group type: COMPARATOR
Intervention: Control group (number not specified)
Number of subjects: 1373
Study 342692 — intervention group
Group type: EXPERIMENTAL
Intervention: L-histidine 4.5 g daily for 30 weeks
Number of subjects: 0
Study 342692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31839621 — intervention group
Group type: EXPERIMENTAL
Intervention: GD-DAPT
Number of subjects: 5131
Study 31839621 — intervention group
Group type: EXPERIMENTAL
Intervention: GD-DAPT (in ACS patients)
Number of subjects: 5131
Study 31419622 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component nurse-led intervention including nurse-led care coordination, nurse-managed medication protocols and adherence support, home BP monitoring, and electronic health records support tools.
Number of subjects: 300
Study 31419622 — intervention group
Group type: COMPARATOR
Intervention: Usual care with generic prevention education (control group).
Number of subjects: 300
Study 28095832 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-sensor biofeedback treatment in addition to guidelines-based care
Number of subjects: 83
Study 28095832 — intervention group
Group type: COMPARATOR
Intervention: Guidelines-based care alone
Number of subjects: 83
Study 26383176 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical aromatherapy 3 times a week for 4 weeks
Number of subjects: 14
Study 26383176 — intervention group
Group type: COMPARATOR
Intervention: Control therapy 3 times a week for 4 weeks
Number of subjects: 14
Study 23149074 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate gazpacho consumption
Number of subjects: 3995
Study 23149074 — intervention group
Group type: EXPERIMENTAL
Intervention: High gazpacho consumption
Number of subjects: 3995
Study 23149074 — intervention group
Group type: COMPARATOR
Intervention: Gazpacho consumption (250 g/week increase)
Number of subjects: 3995
Study 23149074 — intervention group
Group type: COMPARATOR
Intervention: High gazpacho consumption groups
Number of subjects: 3995
Study 21623468 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein enriched dairy product with high leucine content (Test)
Number of subjects: 47
Study 21623468 — intervention group
Group type: COMPARATOR
Intervention: Regular dairy product (Control)
Number of subjects: 47
Study 18470670 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride
Number of subjects: 142
Study 18470670 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 142
Study 18470670 — intervention group
Group type: COMPARATOR
Intervention: No additive treatment (Control)
Number of subjects: 142
Study 16873795 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes risk score based on age, BMI, waist circumference, hypertension, and family history of diabetes
Number of subjects: 2677